Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS by Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth

Get full text

Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. by Yaping Chang, Gordon H Guyatt, Trevor Teich, Jamie L Dawdy, Shaneela Shahid, Jessica K Altman, Richard M Stone, Mikkael A Sekeres, Sudipto Mukherjee, Thomas W LeBlanc, Gregory A Abel, Christopher S Hourigan, Mark R Litzow, Laura C Michaelis, Shabbir M H Alibhai, Pinkal Desai, Rena Buckstein, Janet MacEachern, Romina Brignardello-Petersen

Get full text

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia by Athalia R. Pyzer, Laura W. Dillon, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Gege Gui, Georgia Andrew, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Christopher S. Hourigan, Wendy Stock, Hongtao Liu

Get full text